PAR Technology Corporation, together with its subsidiaries, provides omnichannel cloud-based hardware and software solutions to the worldwide. The company offers PUNCHH, an enterprise-grade customer loyalty and engagement solution; PAR ORDERING, an e-commerce platform; PAR RETAIL, a digital engagement software solution; and PLEXURE, an international customer engagement and loyalty platform under the ENGAGEMENT CLOUD. It also provides PAR POS, a point-of-sale solution; TASK, an enterprise-grade technology solution; PAR OPS, which includes Data Central and Delaget; and PAR PAY, such as PAR payment services, and merchant services under the OPERATOR CLOUD. In addition, the company offers point-of-sale terminals and tablets, wireless headsets, drive-thru systems, kitchen display systems, kiosks, printers, payment devices, and other in-store peripherals. Further it provides services, such as hardware repair, installation and implementation, training, and on-site and technical support services. It serves enterprise restaurants, franchisees, and other restaurant outlets and to C-Stores; and other retail customers, including amusement parks, cinemas, cruise lines, spas, casinos, and other ticketing and entertainment venues. The company was founded in 1968 and is headquartered in New Hartford, New York.

PAR Technology Corporation

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in the indirect interes...

Paradigm Biopharmaceuticals Updates Director Matthew Fry’s Option Holdings

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has reported a change in the interests...

Paradigm Biopharmaceuticals updates market on director Paul Rennie’s expanded option holdings

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has applied for the quotation of 10,139,313 ne...

Paradigm Biopharmaceuticals Seeks ASX Quotation for Over 10 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has released an updated top holders report for ...

Paradigm Biopharmaceuticals’ Top 20 Option Holders Control Majority of PAROPTWC Register

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has applied to the ASX for quotation of a new class of ...

Paradigm Biopharmaceuticals Seeks ASX Quotation for 117 Million New Options

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s indire...

Paradigm Director Increases Stake via Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has announced changes to the interests of direc...

Paradigm Director Paul Rennie Increases Stake Through Additional Share Purchases

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Disc Medicine (IRON), Molecular Partners (MOLN) and ...

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals Limited has announced the cessation of 1,352,8...

Paradigm Biopharmaceuticals Redeems Over 1.3 Million Convertible Notes

Park Dental Partners, Inc. ( ($PARK) ) has provided an update. On May 29, 2026, Park Dental Partners, Inc. held its 2026 Annual Meeting of Sharehol...

Park Dental Shareholders Approve Director Election and Auditor

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX of 7,657,720 new...

Paradigm Biopharmaceuticals Seeks Quotation for 7.7 Million New Shares on ASX

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has updated its disclosure to the ASX regarding...

Paradigm Biopharmaceuticals Corrects Share Purchase Plan Details in ASX Filing

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has completed an oversubscribed Share Purchase Pl...

Market Cap	$1.57B	P/E Ratio	N/A
52W High	$72.15	52W Low	$11.59
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	6.4%	52W Position	6.1%
Overall Score	56	Value Score	60
Quality Score	47	Technical Score	63

EPS Current Est	$-0.28	EPS Next Est	$0.28
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PAR	$15.29	+2.96%	1.54M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PAR	$15.29	+3.0%	1.54M
3
4
5
6

PAR

PAR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get PAR Technology Corporation Data in Excel

Get PAR Technology Corporation Data in Excel